Key result
AI shows potential in AFib detection and management but needs randomized trials confirming prognostic benefit.
Why the study?
Despite updated guidelines, the gradual onset and stroke risk of AF pose clinical challenges, prompting a focus on the progress and knowledge gaps regarding AI use across AF management.
Answers are grounded in this paper and cite their sources.
AI and machine learning algorithms offer promising tools for the detection, risk stratification, and management of atrial fibrillation, but require further validation in prospective randomized clinical trials to demonstrate improved prognosis.
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide. Although the guidelines for AF have been updated in recent years, its gradual onset and associated risk of stroke pose challenges for both patients and cardiologists in real-world practice. Artificial intelligence (AI) is a powerful tool in image analysis, data processing, and for establishing models. It has been widely applied in various medical fields, including AF. In this review, we focus on the progress and knowledge gap regarding the use of AI in AF patients and highlight its potential throughout the entire cycle of AF management, from detection to drug treatment. More evidence is needed to demonstrate its ability to improve prognosis through high-quality randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2024) conducted a review in Atrial fibrillation. Artificial Intelligence was evaluated. Artificial intelligence demonstrates significant potential in the detection, risk stratification, and management of atrial fibrillation, though high-quality randomized controlled trials are needed to confirm its ability to improve prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: